arznei-telegramm Logo a-t Kurzlogo
    ❮ a-t 4/2012 a-t ❯
    This is a translation of the table of contents. One article of each issue is translated and freely available.
    table of contents
    SPOT ON

    Orphan drug pirfenidone (ESBRIET): benefit legally enacted

    Summary of product characteristics - updated at a snail´s pace

    NEW ON THE MARKET

    Botulinum toxin type A (BOTOX) against chronic migraine

    a-t READER'S QUESTIONS AND COMMENTS

    Discount contracts: boon or bane?

    Tamoxifen and CYP 2D6 testing: what´s new?

    IN BRIEF

    Recourse due to fictitiously approved drugs

    Pancreatitis - sitagliptin (JANUVIA, XELEVIA) safety study is overdue

    Confirmed - ADHD more often diagnosed in the youngest children of a class

    Association Voluntary Self-Regulation for the Pharmaceutical Industry (Freiwillige Selbstkontrolle für die Arzneimittelindustrie e.V.) on "ordering" of samples via the courier

    CURRENT ADR NETWORK REPORT

    Fatal rhabdomyolysis following isotretionin
    free

    SIDE EFFECTS

    Severe allergy to mould fungus homeopathics

    Severe hypersensitivity reaction against gout medication febuxostat (ADENURIC)

    New contraindication for strontium ranelate (PROTELOS)

    e a-t IN INTERNET

    Fictitiously approved drugs: information supplementing the in brief story

    arznei-telegramm

    Independent drug information – in English

    Concise, critical evaluations of drugs and medical devices for evidence-based therapy and patient advice on benefits and risks – independent, ad-free and funded exclusively by subscriptions.

    Browse free articles